- Home
- SHLS vs ETON Comparison
SHLS vs ETON Comparison
Compare SHLS & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SHLS | ETON |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SHLS | ETON |
|---|---|---|
| Price | $8.71 | $41.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 3 |
| Target Price | $9.07 | ★ $39.33 |
| AVG Volume (30 Days) | ★ 6.0M | 522.3K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.86 | N/A |
| EPS | ★ 0.07 | 0.05 |
| Revenue | ★ $475,331,000.00 | $79,950,000.00 |
| Revenue This Year | $26.24 | $40.90 |
| Revenue Next Year | $11.52 | $47.23 |
| P/E Ratio | ★ $122.29 | $870.30 |
| Revenue Growth | 19.07 | ★ 104.94 |
| 52 Week Low | $4.45 | $14.27 |
| 52 Week High | $13.18 | $50.18 |
Technical Indicators
Market Signals| Indicator | SHLS | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 43.30 | 49.82 |
| Support Level | $7.61 | $15.77 |
| Resistance Level | $9.91 | $50.18 |
| Average True Range (ATR) | 0.70 | 2.62 |
| MACD | -0.05 | -0.66 |
| Stochastic Oscillator | 28.03 | 16.51 |
Price Performance
Historical ComparisonAbout SHLS Shoals Technologies Group Inc.
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.